These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17356052)

  • 1. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
    Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
    Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
    Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
    Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
    Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from human mutations in PPARgamma.
    Hegele RA
    Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
    Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
    Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
    Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
    Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel
    Zhou L; Li S; Ren J; Wang D; Yu R; Zhao Y; Zhang Q; Xiao X
    Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E357-E370. PubMed ID: 39017680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
    Agarwal AK; Garg A
    J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.
    Soares RMV; da Silva MA; Campos JTAM; Lima JG
    Front Endocrinol (Lausanne); 2024; 15():1394102. PubMed ID: 39398333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
    Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
    Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
    Li G; Leff T
    Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
    Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.